By Darcy Reddan ( October 16, 2019, 4:09 PM EDT) -- Cabaletta Bio, which develops treatments for autoimmune diseases, said Wednesday it is planning to raise $87 million in its Goodwin Procter-led initial public offering if the shares are priced at midpoint....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.